234 related articles for article (PubMed ID: 32470492)
41. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
42. Renal effects of canagliflozin in type 2 diabetes mellitus.
Perkovic V; Jardine M; Vijapurkar U; Meininger G
Curr Med Res Opin; 2015 Dec; 31(12):2219-31. PubMed ID: 26494163
[TBL] [Abstract][Full Text] [Related]
43. Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program.
Wang KM; Li J; Bhalla V; Jardine MJ; Neal B; de Zeeuw D; Fulcher G; Perkovic V; Mahaffey KW; Chang TI
Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00247. PubMed ID: 34277971
[TBL] [Abstract][Full Text] [Related]
44. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
Weir MR; Kline I; Xie J; Edwards R; Usiskin K
Curr Med Res Opin; 2014 Sep; 30(9):1759-68. PubMed ID: 24786834
[TBL] [Abstract][Full Text] [Related]
45. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.
Weir MR
Postgrad Med; 2016; 128(3):290-8. PubMed ID: 26821720
[TBL] [Abstract][Full Text] [Related]
46. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
47. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care.
Wang DD; Zhang C; Yang Y; He SM; Zhu P; Chen X
J Diabetes Res; 2022; 2022():5854200. PubMed ID: 35910530
[TBL] [Abstract][Full Text] [Related]
48. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; de Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V
Circulation; 2019 Aug; 140(9):739-750. PubMed ID: 31291786
[TBL] [Abstract][Full Text] [Related]
49. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
Oshima M; Neuen BL; Jardine MJ; Bakris G; Edwards R; Levin A; Mahaffey KW; Neal B; Pollock C; Rosenthal N; Wada T; Wheeler DC; Perkovic V; Heerspink HJL
Lancet Diabetes Endocrinol; 2020 Nov; 8(11):903-914. PubMed ID: 33065060
[TBL] [Abstract][Full Text] [Related]
50. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Waijer SW; Xie D; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; von Eynatten M; Inker LA; Wanner C; Heerspink HJL
J Am Heart Assoc; 2020 Sep; 9(18):e016976. PubMed ID: 32893717
[TBL] [Abstract][Full Text] [Related]
51. Back off to better blow up: acute GFR decrease at SGLT-2 inhibitor initiation.
Laville M
Kidney Int; 2021 Apr; 99(4):814-816. PubMed ID: 33745548
[TBL] [Abstract][Full Text] [Related]
52. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.
Barraclough JY; Yu J; Figtree GA; Perkovic V; Heerspink HJL; Neuen BL; Cannon CP; Mahaffey KW; Schutte AE; Neal B; Arnott C
Diabetes Obes Metab; 2022 Jun; 24(6):1072-1083. PubMed ID: 35166429
[TBL] [Abstract][Full Text] [Related]
53. Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization.
Khurana M; Vaidyanathan J; Marathe A; Mehrotra N; Sahajwalla CG; Zineh I; Jain L
J Clin Pharmacol; 2015 Jun; 55(6):647-56. PubMed ID: 25612234
[TBL] [Abstract][Full Text] [Related]
54. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.
Arnott C; Neuen BL; Heerspink HJL; Figtree GA; Kosiborod M; Lam CS; Cannon CP; Rosenthal N; Shaw W; Mahaffey KW; Jardine MJ; Perkovic V; Neal B
Int J Cardiol; 2020 Nov; 318():126-129. PubMed ID: 32569700
[TBL] [Abstract][Full Text] [Related]
55. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Desai M; Yavin Y; Balis D; Sun D; Xie J; Canovatchel W; Rosenthal N
Diabetes Obes Metab; 2017 Jun; 19(6):897-900. PubMed ID: 28083972
[TBL] [Abstract][Full Text] [Related]
56. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.
Neal B; Perkovic V; Mahaffey KW; Fulcher G; Erondu N; Desai M; Shaw W; Law G; Walton MK; Rosenthal N; de Zeeuw D; Matthews DR;
Diabetes Obes Metab; 2017 Jul; 19(7):926-935. PubMed ID: 28244644
[TBL] [Abstract][Full Text] [Related]
57. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
58. Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
Heerspink HJL; Sjöström CD; Inzucchi SE; Hallow MK; Cain VA; Rossing P; Stefansson BV; Sartipy P
Diabetes Obes Metab; 2019 Mar; 21(3):720-725. PubMed ID: 30414240
[TBL] [Abstract][Full Text] [Related]
59. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Blevins TC; Farooki A
Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216
[TBL] [Abstract][Full Text] [Related]
60. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
